e15189 Background: This work describes epidemiologic characteristics in anal cancer, in the United States is 1% to 2% of bowel cancers and 3.9% of anorectal carcinomas. Statistics for anal cancer are unknown in our specific Colombia region. Methods: We performed a descriptive preliminary retrospective analysis of 50% of our total patients from Oncologos del Occidente like a private treatment cancer center from January of 1997 to June 2012. Results: 10,000 records were reviewed with 663 colorectoanal cancer and 47 were anal cancer; median age 60.064 (range 32-88. SD. 12.595), 64% female and 96% urban areas; Clinical stage II 32%, stage IIIA 14%, stage IIIB 30%, and 23% were unknown stage; Squamous cell carcinoma including basaloid 79%, adenocarcinoma 17%; Well differentiated 32%, moderately 19% and poorly 19%; 6% had Radical perineal surgery, 81% received chemoradiation (QT/RT), 13% without treatment and 2% were treated with sequential QT+RT; 19% relapsed and 70% of them were local with 87% without any treatment. Gap of RT was 1 to 14 days (11%), 15 to 30 days (23%), 31 to 106 days (15%). No gap (0 days) 51%, Gap mean 13.085 (Range 0-106 SD. 19.534); The initial QT Regimen was 5FU/mitomycin 60%, 5 FU/cisplatinum 4%, capecitabine / mitomycin C in 11%; General survival to 5 years 60% Stage II and 38% Stage III, median survival for Stage III 35%; Mean follow up 43.10 months (range 0 - 178. SD. 45.5), Gap Survival to 5 years was 36% without rest with a median of 20 months, Gap of 1 to 14 days with a median of 35 months and 40% of survival to 5 years; and 55% from 15-30 days of survival to 5 years (p> 0.05). Conclusions: These results reflect the occurrence pattern of anal cancer in a specific area of Colombia, and the importance of a multidisciplinary treatment group.